Clinical Trials Logo

Clinical Trial Summary

This is a Phase II single center, open-label, single arm study in patients with advanced thymic epithelial tumors after failure of cisplatin-based combination chemotherapy. Patients will be treated with Pembrolizumab 200 mg every 3 weeks.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02607631
Study type Interventional
Source Samsung Medical Center
Contact
Status Completed
Phase Phase 2
Start date November 2015
Completion date August 2018

See also
  Status Clinical Trial Phase
Recruiting NCT02146170 - Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors